Latest News about BMY
Recent news which mentions BMY
Ventyx Jumps Over 20% Today After NASDAQ Debut
Today 13:20 EDT
From Benzinga
Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg
Today 13:10 EDT
From Benzinga
From Benzinga
Could This Beaten-Down Biotech Stock Be the Next Buyout Target?
October 20, 2021
From Motley Fool
From Benzinga
Why Infinity Pharmaceuticals Shot Nearly 4% Higher Today
October 18, 2021
From Motley Fool
2 Best Biotech Stocks to Buy Right Now
October 18, 2021
From Motley Fool
2 Top Biotech Stocks to Buy in October
October 18, 2021
From Motley Fool
3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More
October 15, 2021
From Motley Fool
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
October 14, 2021
From Benzinga
MINDCURE's "Desire Project" uses MDMA to Treat Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
October 12, 2021
From Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
October 12, 2021
From Benzinga
3 Top Warren Buffett Stocks to Buy in October
October 10, 2021
From Motley Fool
Evotec Expands Neuroscience Collaboration with Bristol Myers
October 08, 2021
From Benzinga
5 Warren Buffett Stocks to Buy Hand Over Fist for the Fourth Quarter
October 08, 2021
From Motley Fool
Is an Acquisition of Acceleron a Smart Move for Merck?
October 08, 2021
From Motley Fool
From Benzinga
From Benzinga
From Motley Fool
This Healthcare Company Is Using AI to Develop Drugs
October 03, 2021
From Motley Fool
2 Ridiculously Cheap Growth Stocks to Buy
October 02, 2021
From Motley Fool
Bristol Myers Squibb: Should You Buy the Dip?
October 02, 2021
From Motley Fool
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
October 01, 2021
From Benzinga
From Motley Fool
Merck Seals Acceleron Pharma Deal For $180/Share: Highlights
September 30, 2021
From Benzinga
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
September 29, 2021
From Motley Fool
AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan
September 28, 2021
From Benzinga
Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ
September 28, 2021
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Market Action
MARKET NEWS
Home | Individual investors | Institutional investors | Find an advisor | Opportunities at Winslow | About | News | Contact | Mobile | Site map
Privacy | Legal notices | Copyright 2021 Winslow, Evans & Crocker
Investing involves risk including loss of principal. Securities and Variable Insurance Products offered through National Securities Corporation, member FINRA/ SIPC. Fee-based investment advisory services offered through National Asset Management, an SEC registered investment advisor. Insurance products, including fixed indexed annuities offered through National Insurance Corporation.
Privacy | Legal notices | Copyright 2021 Winslow, Evans & Crocker
Investing involves risk including loss of principal. Securities and Variable Insurance Products offered through National Securities Corporation, member FINRA/ SIPC. Fee-based investment advisory services offered through National Asset Management, an SEC registered investment advisor. Insurance products, including fixed indexed annuities offered through National Insurance Corporation.